State attorneys general want to lower Gilead's high remdesivir prices with federal patent law

Gilead.
(Image credit: JOSH EDELSON/AFP via Getty Images)

The antiviral drug remdesivir's effectiveness at combating the coronavirus has been one of the biggest breakthroughs since the pandemic began. The catch is that the Gilead treatment is expensive and in short supply. So, a bipartisan group of state attorneys general are looking to the federal government to step in and change that.

In a letter to the heads of the Department of Health and Human Services, the National Institutes of Health, and the Food and Drug Administration, 31 attorneys general asked the agencies to exercise march-in rights granted to them by the 1980 Bayh-Dole Act to increase the supply of the drug and lower the price so it becomes more accessible to Americans.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.